FRA:IUI1 • US46120E6023
The current stock price of IUI1.DE is 423.7 EUR. Today IUI1.DE is up by 0.32%. In the past month the price increased by 4.68%. In the past year, price decreased by -5.1%.
ChartMill assigns a technical rating of 1 / 10 to IUI1.DE. When comparing the yearly performance of all stocks, IUI1.DE is a bad performer in the overall market: 81.53% of all stocks are doing better.
ChartMill assigns a fundamental rating of 7 / 10 to IUI1.DE. IUI1.DE has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
On January 22, 2026 IUI1.DE reported an EPS of 2.53 and a revenue of 2.87B. The company beat EPS expectations (9.85% surprise) and beat revenue expectations (2.22% surprise).
42 analysts have analysed IUI1.DE and the average price target is 527.49 EUR. This implies a price increase of 24.49% is expected in the next year compared to the current price of 423.7.
For the next year, analysts expect an EPS growth of 14.45% and a revenue growth 15.88% for IUI1.DE
Over the last trailing twelve months IUI1.DE reported a non-GAAP Earnings per Share(EPS) of 7.73. The EPS increased by 21.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 28.38% | ||
| ROA | 13.96% | ||
| ROE | 16.02% | ||
| Debt/Equity | 0 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 2M6 | MEDTRONIC PLC | 14.35 | 97.986B | ||
| SHL | SIEMENS HEALTHINEERS AG | 14.89 | 44.026B | ||
| PHI1 | KONINKLIJKE PHILIPS NV | 16.16 | 23.794B | ||
| PHIA | KONINKLIJKE PHILIPS NV | 15.96 | 23.707B | ||
| BIM | BIOMERIEUX | 19.49 | 11.167B | ||
| DIA | DIASORIN SPA | 15.63 | 3.624B | ||
| OBCK | OTTOBOCK SE & CO KGAA | 17.77 | 3.423B | ||
| AFX | CARL ZEISS MEDITEC AG - BR | 11.56 | 2.111B | ||
| DRW3 | DRAEGERWERK AG - PREF | 10.89 | 1.601B | ||
| DRW8 | DRAEGERWERK AG | 8.61 | 1.287B | ||
| ELN | EL.EN. SPA | 20.39 | 1.008B | ||
| EUZ | ECKERT & ZIEGLER SE | 17.59 | 943.272M | ||
| GVS | GVS SPA | 12.15 | 669.697M |
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. The company is headquartered in Sunnyvale, California and currently employs 17,021 full-time employees. The company went IPO on 2000-06-13. The firm specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
IPO: 2000-06-13
INTUITIVE SURGICAL INC
1020 Kifer Road
Sunnyvale CALIFORNIA US
Employees: 17021
Phone: 13026587581
Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. The company is headquartered in Sunnyvale, California and currently employs 17,021 full-time employees. The company went IPO on 2000-06-13. The firm specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
The current stock price of IUI1.DE is 423.7 EUR. The price increased by 0.32% in the last trading session.
IUI1.DE does not pay a dividend.
IUI1.DE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
IUI1.DE stock is listed on the Frankfurt Stock Exchange exchange.
The Revenue of INTUITIVE SURGICAL INC (IUI1.DE) is expected to grow by 15.88% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.